Daniel Vitt - 16 Jul 2025 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Role
CEO and Director, Director
Signature
/s/ Daniel Vitt
Issuer symbol
IMUX
Transactions as of
16 Jul 2025
Transactions value $
$0
Form type
4
Filing time
18 Jul 2025, 16:05:56 UTC
Previous filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vitt Daniel CEO and Director, Director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK /s/ Daniel Vitt 18 Jul 2025 0001773673

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMUX Stock Appreciation Right Award $0 +860K $0.00 860K 16 Jul 2025 Common Stock 860K $0.77 Direct F1
transaction IMUX Stock Appreciation Right Award $0 +1.72M $0.00 1.72M 16 Jul 2025 Common Stock 1.72M $0.77 Direct F1, F2
transaction IMUX Stock Appreciation Right Award $0 +1.72M $0.00 1.72M 16 Jul 2025 Common Stock 1.72M $0.77 Direct F1, F3
transaction IMUX Stock Appreciation Right Award $0 +860K $0.00 860K 16 Jul 2025 Common Stock 860K $0.77 Direct F1, F4
transaction IMUX Stock Appreciation Right Award $0 +860K $0.00 860K 16 Jul 2025 Common Stock 860K $0.77 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.
F2 Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.
F3 Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.
F4 Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").
F5 Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.